course of treatment, and follow-up for vital status (through linkage with the National Death Index data from the National Center for Health Statistics). The SEER Program is considered the standard for quality among cancer registries around the world. Quality control has been an integral part of SEER since its inception. Every year, studies are conducted in SEER areas to evaluate the quality and completeness of the data being reported.
For this analysis, we included 6957 patients who were younger than 15 years at fi rst diagnosis of an acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, Hodgkin lymphoma, or nonHodgkin lymphoma between 1980 and 2004 that was reported to a population-based SEER Program registry; had no prior malignancy; and were followed up for vital status until December 31, 2004 . Patients whose cancer was diagnosed by autopsy (n = 6) or reported only on a death certifi cate (n = 6) were excluded, leaving 6945 patients (99.8%) for the analysis.
We calculated 5-and 10-year survival for three calendar periods -1990 -1994, 1995 -1999, and 2000 -2004 -using the period analysis method ( 10 , 13 ) ; 95% confi dence intervals (CIs) were calculated as described by Rothman ( 14 ) , using Greenwood ' s ( 15 ) variance equation. We also tested the statistical signifi cance of trends in 5-and 10-year year survival between the earliest and the latest of these calendar periods (ie, 1990 -1994 and 2002 -2004 , respectively) by using a modeling approach that was described by Brenner and Hakulinen ( 11 ) . Survival was analyzed overall and according to sex. Due to case number limitations, age-specifi c analyses were performed for children with acute lymphoblastic leukemia only.
Briefl y, period analysis consists of restricting the analysis to survival during a period of interest, which is achieved by left truncation of observations at the beginning of the period and right censoring of observations at the end of the study period. In this analysis, survival was monitored in 5-year periods of follow-up rather than in 5-year cohorts of patients (ie, patients diagnosed in defi ned 5-year periods). For example, a period estimate of 10-year survival for 2000 -2004 using follow-up data available up to the year 2004 exclusively refl ects the survival experience between 2000 and 2004, as shown in Figure 1 (solid frame). With this approach, the survival experience during the early years of follow-up, which is when most cancer-related deaths occur, is derived exclusively from patients who were diagnosed more recently. By contrast, the most up-todate estimate of 10-year survival obtained by traditional "cohort analysis" would refl ect survival experience of patients who were diagnosed and treated 10 years earlier, that is, between 1990 and 1994 ( Figure 1 , dashed frame).
Extensive empiric evaluation has shown that period analysis provides more up-to-date long-term survival estimates than cohortbased survival analysis and predicts long-term survival expectations of cancer patients diagnosed within the period of interest quite well ( 16 -18 ) . We also derived survival projections for the 2005 -2009 period by using a novel modeling approach ( 19 ) . First, we calculated the number of patients at risk and the number of deaths by year of follow-up for each of the three preceding 5-year periods (1990 -1994, 1995 -1999, and 2000 -2004) , just as we did in the conventional period analysis. Next, we estimated and tested for survival trends between the 1990 -1994 period and the 2000 -2004 period and used those estimates to project survival for the 2005 -2009 period by using a previously described and validated ( 19 ) Poisson regression model. Briefl y, the number of deaths for each combination of 5-year calendar period and year of follow-up was modeled as a function of the calendar period and the year of follow-up. On the basis of this model, we calculated the projected numbers of deaths and the conditional survival probabilities for each year of 
CONTEXT AND CAVEATS

Prior knowledge
The available estimates of long-term survival for survivors of childhood hematologic malignancies are based on data from children who were diagnosed in the early and mid-1990s and thus may not reflect the possible impact of recent advances in treatment on survival.
Study design
A period analysis of 5-and 10-year survival probabilities for US children diagnosed before the age of 15 years with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma diagnosed during three recent 5-year intervals -1990 -1994, 1995 -1999, and 2000 -2004 based on Surveillance, Epidemiology, and End Results data for 6957 patients.
Contribution
Both 5-and 10-year survival of children diagnosed with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, and nonHodgkin lymphoma have improved from the 1990 -1994 period to the 2000 -2004 period. The 5-and 10-year survival rates for children diagnosed with Hodgkin lymphoma during the 1990 -1994 period (96.1% and 94.4%, respectively) did not change substantially in the later time periods.
Implications
Improvements in survival in childhood hematologic malignancies are most likely attributable to changes in how these diseases are treated. The timely disclosure of these improvements may encourage compliance with available and effective therapies.
Limitations
The 95% confidence intervals for some survival estimates were wide. Even with period analysis, the estimates of survival for the 2000 -2004 period tend to underestimate the survival of newly diagnosed patients. period using period analysis. The dashed frame shows the data used to derive the most up-to-date estimate of 10-year survival from the same database (pertaining to the 1990 -1994 cohort) using traditional cohort analysis. The numbers within the cells indicate the number of years of follow-up since diagnosis. For example, for patients diagnosed in 1991, the fi rst year of follow-up is spread over the years 1991 and 1992, the second year of follow-up is spread over the years 1992 and 1993, and so on.
From the Editors
We also estimated 25-year survival curves in the 2000 -2004 period for children with hematologic malignancies to address concerns about the potential long-term effects of novel effective treatment regimens. All analyses were performed using SAS statistical software, version 9.1 (SAS Institute, Cary, NC) and used adapted versions of previously described macros for conventional ( 16 ) and modeled ( 19 ) period analysis.
Results
The number of children aged 15 years or younger who were diagnosed with leukemia or lymphoma between the 1990 -1994 and 2000 -2004 time periods is shown in Table 1 . ( Tables 2 and 3 ). For those diagnosed with acute lymphoblastic leukemia, 5-year survival increased from 80.2% to 87.5% and 10-year survival increased from 73.4% to 83.8% ( P trend < .001 in both cases). Because the absolute increase in 10-year survival was greater than for 5-year survival (+10.4 vs +7.3 percentage points, respectively), the difference between the 5-and 10-year estimates for children diagnosed with acute lymphoblastic leukemia was less in the 2000 -2004 period (4.2%) than in the 1990 -1994 period (6.8%). The increase in both 5-and 10-year survival from the 1990 -1994 period to the 2000 -2004 period was greatest for children who were 10 -14 years old at diagnosis and who traditionally have a poorer prognosis. Thus, the survival disadvantage of patients in this age group compared with patients in the other age groups diminished. For the other hematologic malignancies, case numbers were too small to derive age-specifi c survival estimates with reasonable precision; see also Methods. For children diagnosed with acute non-lymphoblastic leukemia, 5-year survival increased by 18 percentage points, from 41.9% in the 1990 -1994 period to 59.9% in the 2000 -2004 period ( P trend < .001), and 10-year survival increased by 20.4 percentage points, from 38.7% to 59.1% ( P trend < .001). For children diagnosed with any type of leukemia, 5-year survival increased from 73.0% to 82.5% and 10-year survival increased from 66.8% to 79.4% ( P trend < .001 for both). Substantial increases in survival were also seen for those diagnosed with non-Hodgkin lymphoma: 5-year survival increased by 11.1 percentage points, from 76.6% to 87.7%, and 10-year survival increased by 13.9 percentage points, from 73.0% to 86.9% ( P trend = .015 and P trend = .005, respectively). For those diagnosed with Hodgkin lymphoma, 5-and 10-year survival for the 1990 -1994 period were already as high as 96.1% and 94.4%, respectively, and did not change substantially in the later time periods. In the 2000 -2004 period, 5-and 10-year survival were both 95.4%, that is, not a single death occurred among children diagnosed with Hodgkin lymphoma between 5 and 10 years after diagnosis. When all lymphomas were considered together, 5-year survival increased from 84.7% to 91.0% ( P trend = .01) and 10-year survival increased from 82.6% to 89.9% ( P trend = .006) between the 1990 -1994 period and the 2000 -2004 period.
Improvements in survival were observed in both sexes. In most cases, period estimates of survival were higher in girls with leukemia than in boys with leukemia. However, the differences between the period estimates were generally small and the confi dence intervals overlapped. In the 2000 -2004 period, 85.1% of girls ( Tables 2 and 3 ).
The 25-year survival curves for children diagnosed with four common hematologic malignancies based on period estimates for the 2000 -2004 calendar period are shown in Figure 3 . Survival curves continued to decline over the entire 25-year period for all hematologic malignancies. This pattern was most pronounced for Hodgkin lymphoma: despite the much higher survival of children with Hodgkin lymphoma up to 10 years after diagnosis, the 25-year survival of children with Hodgkin lymphoma, acute lymphoblastic leukemia, and non-Hodgkin lymphoma was expected to be about the same, that is, close to 80%.
Discussion
Our findings indicate that survival of children diagnosed with three of the four most common childhood hematologic malignancies -acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, and non-Hodgkin lymphoma -has further improved from the 1990 -1994 period to the 2000 -2004 period. In particular, 10-year survival increased by more than 20 percentage points for acute non-lymphoblastic leukemia. Moreover, comparisons of 5-and 10-year survival rates suggest that deaths due to a late relapse of these hematologic malignancies may be decreasing. Projections for the 2005 -2009 period suggest that the chances of 10-year survival are close to 90% or higher for children diagnosed with acute lymphoblastic leukemia, Hodgkin lymphoma, or non-Hodgkin lymphoma and close to 65% for children diagnosed with acute non-lymphoblastic leukemia. Compared with traditional methods for estimating survival, the period analysis used in this study provides more up-to-date estimates of long-term survival ( 16 -18 ) . Most recent population-based studies on childhood leukemia and lymphoma incidence and survival have used cohort or complete analysis and presented survival data only up to the mid-1990s ( 6 -9 ). For example, in the Automated Childhood Cancer Information System project, 5-year survival of children diagnosed with acute lymphoblastic leukemia and acute non-lymphoblastic leukemia during 1993 -1997 was 82% and 53%, respectively, for European registries combined and 87% and 56%, respectively, for Northern Europe, the European region with the highest survival rates ( 6 ) . For Hodgkin lymphoma and nonHodgkin lymphoma, 5-year survival estimates were 95% and 77% for Europe combined and 95% and 83% for western Europe, the European region with the highest lymphoma survival rates ( 7 , 8 ) . Our survival estimates for the 1995 -1999 period are close to the best European estimates for children diagnosed with acute lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma during 1993 -1997. For children diagnosed with acute non-lymphoblastic leukemia, our survival estimates for 1995 -1999 were considerably lower than the best European estimates but similar to those for children diagnosed with acute non-lymphoblastic leukemia in Northern and Western Europe in the 1980s ( 6 ) To our knowledge, this is the fi rst study to apply a modeled period analysis to project survival estimates for children recently diagnosed with hematologic malignancies. Although projected period estimates of survival are expected to be even more up-todate than conventional period estimates because they overcome the common delay in availability of cancer registry data ( 19 ) , period estimates are statistically less precise and their validity depends on the validity of the underlying assumptions, especially the assumption that previously observed trends will continue. A fi nal judgment of the validity of our projections will only be possible in retrospect a few years from now. However, the model-based projection method has been extensively validated in adult cancer patients, for whom it has been found to provide much better estimates of survival of recently diagnosed patients than all other methods, including conventional period analysis in most cases ( 19 ) . Table 2 , and for 19 of the 22 estimates of 10-year survival shown in Table 3 , the difference between the projected estimates and the actual estimates was smaller than the difference between the 1995 -1999 period survival estimates (the most up-to-date conventional period estimates available at the beginning of this century) and the 2000 -2004 period survival estimates (data not shown). This fi nding strongly supports the use of the model-based projection approach for deriving up-to-date survival estimates for children with hematologic malignancies.
With regard to possible reasons for the improved survival of children with hematologic malignancies, there is no evidence that early detection plays a substantial role in improving survival of children with leukemia. Although patients with early-stage lymphoma have better survival than those with late-stage disease, there are no systematic screening programs for lymphoma, and the ability of clinicians to detect lymphoma at early stages has not changed substantially in recent years. Therefore, improvements in survival in childhood hematologic malignancies are most likely attributable to changes in how these diseases are treated.
Much recent research into childhood acute lymphoblastic leukemia has focused on identifying factors associated with the risk of recurrence and ways to decrease the toxic effects of treatment. Four major risk groups have been identifi ed, based on patient and disease characteristics ( 2 ) . Having reliable information on the risk of recurrence has allowed for more intensive treatment of some patients with high-risk disease [ie, early postinduction intensifi cation ( 22 ) ] and, conversely, less intensive -and therefore less toxic -treatment for patients with low-risk disease. One area in which the standard of care has evolved over the past decade is in prophylaxis against leukemic spread into the central nervous system. Previously, all children diagnosed with acute lymphoblastic leukemia received cranial irradiation. However, cranial irradiation is highly toxic to the developing brain and has been found to lead to neurocognitive defi cits in children who survived acute lymphoblastic leukemia ( 4 ). Intrathecal chemotherapy is effective in many patients with acute lymphoblastic leukemia and seems to produce fewer long-term neurologic problems than cranial irradiation ( 23 , 24 ) . Guidelines for the use of intrathecal chemotherapy have been developed and have spared some patients the toxic effects of cranial irradiation.
Unlike childhood acute lymphoblastic leukemia, childhood acute non-lymphoblastic leukemia is still highly lethal and work in this disease has, necessarily, concentrated on improving survival. Fortunately, our period analysis revealed that attempts to improve survival appear to have been successful. Long-term survival is expected to be greater than 60% for children who are diagnosed with acute non-lymphoblastic leukemia from 2005 through 2009. Reasons for the increased survival include improvements in clinicians ' ability to predict relapse, which has allowed for more tailored treatment. Intensifi cation of therapy for acute non-lymphoblastic leukemia, including the administration of intensive high-dose cytarabine, has led to improvements in survival in childhood acute non-lymphoblastic ( 24 ) . In addition, improvements in stem cell transplantation techniques and supportive care have probably played a role in the improvement in survival we observed. Finally, an increasing awareness of the responsiveness of Down syndrome -related acute non-lymphoblastic leukemia to therapy ( 24 ) may have led to better treatment and therefore more longterm survival in this patient group. Down syndome patients are more sensitive to some chemotherapeutic agents and do not, in most cases, benefi t from intensive therapy ( 25 ) . Thus, improvements in the specifi c treatment of this patient cohort may have contributed to the overall improvement we observed.
Non-Hodgkin lymphoma is uncommon in children younger than 15 years compared with adults. When non-Hodgkin lymphoma does occur in children, it is almost always of high-or intermediategrade histology, and the most common histologies are Burkitt lymphoma (35% -40% of childhood cases), diffuse large B-cell lymphoma (15% -20%), lymphoblastic lymphoma (25% -30%), and anaplastic large-cell lymphoma (5% -10%) ( 1 , 12 ) . Although such lymphomas are highly aggressive and can be rapidly fatal, they are also more curable than low-grade lymphomas. With the exception of diffuse large B-cell lymphoma, these histologies necessitate more aggressive treatments than those commonly used in adult non-Hodgkin lymphoma. Therefore, improvements in supportive care and more accurate assessment of risk in younger patients may play more of a role in improving survival in childhood compared with adult non-Hodgkin lymphoma.
Given the young age at which the patients studied were diagnosed, the follow up of at least 25 years is of considerable interest in order to determine whether survivors of childhood hematologic malignancies are at increased risk of death in young adulthood. The estimated persistent decrease in survival between 10 and 25 years after diagnosis for all hematologic malignancies assessed ( Figure 3 ) in the 2000 -2004 period analysis is concerning. Several studies have shown that long-term survivors of childhood hematologic malignancies are vulnerable to a number of health problems later in life. For example, an increased risk of a second malignancy has been observed in survivors of childhood acute lymphoblastic leukemia ( 26 -28 ) . A recent study with up to 30 years of follow-up observed an increased risk of acute non-lymphoblastic leukemia up to 10 years after successful treatment of childhood acute lymphoblastic leukemia and an increased risk of solid tumors that continued for up to 30 years after diagnosis ( 28 ) . Although the risk of brain tumors was lower in children with acute lymphoblastic leukemia who had not received cranial irradiation than in those who had, it was higher in both groups of patients than in the general population ( 27 , 28 ) . Children who are treated with anthracyclines, which are used in the treatment of many common childhood malignancies, are at a higher risk of cardiac complications later in life than those who are not treated with anthracyclines ( 29 , 30 ) . However, this effect is dose dependent and can be mitigated by using the minimum necessary dose. Nevertheless, cardiac disease is a potentially serious late toxic effect of anthracycline therapy. Increased incidences of cardiac disease ( 31 ), second malignancies ( 32 ) , and stroke ( 33 ) have been reported in survivors of childhood Hodgkin lymphoma. In summary, patients who are successfully treated for childhood hematologic malignancies are at increased risk for a number of serious health problems and require close monitoring of their health throughout life.
Our study has some limitations. First, although our survival estimates were based on a large SEER database, some had wide 95% confi dence intervals, especially those in the age-specifi c analyses. Second, although period estimates of survival are more up-todate than estimates from traditional cohort analyses of survival, they tend to underestimate the survival of newly diagnosed patients to some extent ( 19 , 34 ) . In particular, the data we used to generate the 25-year survival curves included patients who were treated with older protocols, and therefore the 25-year survival of recently diagnosed patients who were likely to have been treated with more effective protocols may be underestimated. Thus, the survival rates of children recently diagnosed with hematologic malignancies may be slightly higher than those shown in our analysis.
In summary, our period analysis revealed that survival after diagnosis with childhood hematologic malignancies has improved greatly over the past decade. Survival projections for children diagnosed in the 2005 -2009 period suggest that 10-year survival is at least 90% or higher for those diagnosed with acute lymphoblastic leukemia, nonHodgkin lymphoma, or Hodgkin lymphoma and close to 65% for those diagnosed with acute non-lymphoblastic leukemia. We hope that the timely disclosure of these improvements to patients and their families, clinicians, and the public will reduce the level of fear engendered by a diagnosis of a childhood hematologic malignancy and encourage compliance with available and effective therapies. Further improvements in survival may be observed in the future as newer protocols are incorporated into the treatment of these malignancies.
